Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) ...

Gimeracil used in S-1 is a stronger inhibitor for the intratumoural DPD activity than uracil used in UFT. As a result, S-1 might be more effective for patients with TS-negative, OPRT-positive ...

Oportun Financial Corporation (OPRT) closed the last trading session at $6.90, gaining 57.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price ...